Last reviewed · How we verify

INH, Rifampicin, Ethambutol and Pyrazinamide

All India Institute of Medical Sciences · Phase 3 active Small molecule

INH, Rifampicin, Ethambutol and Pyrazinamide is a Anti-tuberculosis combination therapy Small molecule drug developed by All India Institute of Medical Sciences. It is currently in Phase 3 development for Tuberculosis (drug-susceptible pulmonary and extrapulmonary). Also known as: Category I DOTS.

This is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and mycolic acid production, killing Mycobacterium tuberculosis.

This is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and mycolic acid production, killing Mycobacterium tuberculosis. Used for Tuberculosis (drug-susceptible pulmonary and extrapulmonary).

At a glance

Generic nameINH, Rifampicin, Ethambutol and Pyrazinamide
Also known asCategory I DOTS
SponsorAll India Institute of Medical Sciences
Drug classAnti-tuberculosis combination therapy
TargetMultiple: mycolic acid synthesis (INH), bacterial RNA polymerase (Rifampicin), arabinosyl transferases (Ethambutol), bacterial energy metabolism (Pyrazinamide)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

INH (isoniazid) inhibits mycolic acid synthesis; Rifampicin inhibits bacterial RNA polymerase; Ethambutol inhibits arabinosyl transferases in cell wall synthesis; and Pyrazinamide is converted to pyrazinoic acid which disrupts bacterial energy metabolism. Together, these agents target multiple pathways to prevent resistance and achieve rapid bactericidal activity against tuberculosis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about INH, Rifampicin, Ethambutol and Pyrazinamide

What is INH, Rifampicin, Ethambutol and Pyrazinamide?

INH, Rifampicin, Ethambutol and Pyrazinamide is a Anti-tuberculosis combination therapy drug developed by All India Institute of Medical Sciences, indicated for Tuberculosis (drug-susceptible pulmonary and extrapulmonary).

How does INH, Rifampicin, Ethambutol and Pyrazinamide work?

This is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and mycolic acid production, killing Mycobacterium tuberculosis.

What is INH, Rifampicin, Ethambutol and Pyrazinamide used for?

INH, Rifampicin, Ethambutol and Pyrazinamide is indicated for Tuberculosis (drug-susceptible pulmonary and extrapulmonary).

Who makes INH, Rifampicin, Ethambutol and Pyrazinamide?

INH, Rifampicin, Ethambutol and Pyrazinamide is developed by All India Institute of Medical Sciences (see full All India Institute of Medical Sciences pipeline at /company/all-india-institute-of-medical-sciences).

Is INH, Rifampicin, Ethambutol and Pyrazinamide also known as anything else?

INH, Rifampicin, Ethambutol and Pyrazinamide is also known as Category I DOTS.

What drug class is INH, Rifampicin, Ethambutol and Pyrazinamide in?

INH, Rifampicin, Ethambutol and Pyrazinamide belongs to the Anti-tuberculosis combination therapy class. See all Anti-tuberculosis combination therapy drugs at /class/anti-tuberculosis-combination-therapy.

What development phase is INH, Rifampicin, Ethambutol and Pyrazinamide in?

INH, Rifampicin, Ethambutol and Pyrazinamide is in Phase 3.

What are the side effects of INH, Rifampicin, Ethambutol and Pyrazinamide?

Common side effects of INH, Rifampicin, Ethambutol and Pyrazinamide include Hepatotoxicity, Peripheral neuropathy (INH-related), Hyperuricemia (Pyrazinamide-related), Optic neuritis (Ethambutol-related), Gastrointestinal disturbance, Rash.

What does INH, Rifampicin, Ethambutol and Pyrazinamide target?

INH, Rifampicin, Ethambutol and Pyrazinamide targets Multiple: mycolic acid synthesis (INH), bacterial RNA polymerase (Rifampicin), arabinosyl transferases (Ethambutol), bacterial energy metabolism (Pyrazinamide) and is a Anti-tuberculosis combination therapy.

Related